Daiwa analyst Narumi Nakagiri downgraded AbbVie (ABBV) to Neutral from Outperform with an $180 price target
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Alector downgraded to Underperform at BofA after Alzheimer’s trial miss
- Amazon invests $4B more in Anthropic, Gap reports Q3 beat: Morning Buzz
- Trump Trade: Trump Media considers developing crypto payment service
- AbbVie upgraded, Baidu downgraded: Wall Street’s top analyst calls
- AbbVie upgraded to Outperform from Market Perform at Leerink